Special Issue

Antimicrobial Peptides: A New Hope in the War against Multi-Drug Resistance

Message from the Guest Editor

Large amounts of antibiotics used for human therapy and farm animals have resulted in the selection of pathogenic bacteria resistant to multiple drugs. There is an increasing prevalence of multi-drug resistance (MDR) bacteria globally, which are exceedingly difficult to treat and which constitute a growing health problem. Thus, there is a tremendous interest in developing novel agents as alternative approaches for treating MDR pathogen infections. Antimicrobial peptides (AMPs), also known as host defense peptides, are natural or synthetic peptides with potent antimicrobial activity against diverse micrograms, particularly MDR bacterial pathogens. Due to broad spectrum activity, rapid killing rate, and low drug resistance potential, some AMPs have been proposed to be a promising alternative for the treatment of infections caused by antibioticresistant pathogens. This Special Issue seeks manuscript submissions that further our understanding of AMPs. Submissions on design, expression, structure, antimicrobial activity, mechanism of AMPs which are used to reduce transmission of MDR pathogens are especially encouraged.

Guest Editor

Prof. Dr. Xiumin Wang

Institute of Feed Research, Chinese Academy of Agricultural Sciences, Beijing 100081, China

Deadline for manuscript submissions

closed (30 November 2023)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/122869

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

